Levodopa/Carbidopa Hexal

Levodopa, the active ingredient in Levodopa/Carbidopa Hexal, is a Levodopa/Carbidopa combination presented as an oral tablet for oral use. It is employed to treat the motor symptoms of Parkinson's disease and related Parkinsonian syndromes in adult patients. GNH USA supplies Levodopa/Carbidopa Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Carbidopa acts on the dopaminergic pathway to improve motor function in Parkinsonian disorders. - Parkinson's disease: reduces bradykinesia, rigidity and tremor. - Parkinsonian syndrome: alleviates motor deficits associated with secondary Parkinsonism. - Rest tremor: diminishes tremor amplitude and frequency in affected limbs.

Levodopa/Carbidopa may cause a range of adverse reactions.

Common Side Effects: - Nausea - Vomiting - Dizziness or light‑headedness - Headache - Orthostatic hypotension - Insomnia

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Hallucinations or psychosis - Severe hypotension or syncope - Cardiac arrhythmias - Neuroleptic malignant‑like syndrome

Patients should be monitored for safety concerns before and during therapy. - Monitor blood pressure: check regularly for orthostatic changes. - Assess for dyskinesia: watch for involuntary movements that may require dose adjustment. - Review psychiatric status: observe for hallucinations, confusion, or mood changes. - Adjust dose in renal impairment: consider reduced dosing in patients with decreased renal function. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Levodopa/Carbidopa can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk hypertensive crisis. - Antipsychotics (e.g., haloperidol): may diminish therapeutic effect. - Antihypertensive agents: can cause severe hypotension. - Iron or calcium supplements: decrease levodopa absorption. - High‑protein meals: reduce central levodopa availability.

Moderate Interactions (Monitor Closely): - Selective MAO‑B inhibitors: may increase levodopa plasma levels. - SSRIs or SNRIs: potential for serotonin syndrome when combined with other serotonergic agents.